ArticleThoracic cancer2024

Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.

Takako Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.